The value of treatment! Professor D R Laurence (London) took the Chair and the symposium was introduced by the Section President, Professor Paul Turner. Hitherto the emphasis has been on the safety, quality and efficacy of drugs, but the everincreasing cost of the National Health Service has forced attention on economics. In thirty years the average annual cost of the NHS per head of the population has risen from about £10 in 1951 to over £240 in 1981. In effect, health care is rationed by lack of resources. But it is very difficult to cost. Even a simple, one-month study at St Bartholomew's Hospital comparing pharmacy and outpatient dispensing threw up all sorts of problems requiring arbitrary assumptions, and it revealed numerous hidden costs. In the end an investigation that cost £6000 showed possible savings of £240 a month.
It is even harder to measure the outcome of treatment in either economic or personal terms, but it will become increasingly necessary to do this in order to justify competing claims on inadequate budgets.
Dr G H Mooney (Aberdeen), a health economist, emphasized the gap between economists and the medical profession. Whereas doctors defend their clinical freedom to do what they consider best for the individual patient, economists try to maximize the benefit to society. They try to ensure that scarce resources cannot be put to better use. Economics is more about choice than money. It is a way of thinking in which the doctrine of 'opportunity cost' is central. This is the benefit foregone when resources are not used in an alternative way. The cost of something is what you are prepared to sacrifice in order to obtain it. There is no sure way to get the right answer but it is a great help even to ask the right questions. This will entail sorting the priorities on explicit criteria. The principles are more important than the technique used.
There are two main types of economic analysis. Cost-effectiveness studies seek to maximize output for a fixed cost or to minimize the cost of achieving a stated objective. They have the advantage that the output does not necessarily have to be expressed in monetary terms.
Cost-benefit analysis is done to promote 'allocative efficiency', that is to maximize the benefits from available resources. To do this it is obvious that costs and benefits must be commensurable.
Unfortunately, there is particular difficulty in measuring benefit since it frequently cannot be translated into monetary terms. Nevertheless, if treatment is going to be efficient, doctors must face the problem.
At present they are not taking economic factors sufficiently into account. The ultimate decision on the allocation of resources should be taken by a responsible multidisciplinary group and not by doctors alone. ..,Too often the necessary data and training are both lacking.
Dr H J Goldsmith (Liverpool), speaking on the economics of renal failure, said that advances in high-technology medicine have now outpaced our social and financial capacity to apply them, so that hard decisions have to be made on who should benefit.
More than 1200 renal units are members of the European Dialysis and Transplant Association and the records of more than 12000 patients are held on a computer. Of the available treatments, renal transplants have proved to be cost effective and the treatment of choice. In the UK there is a growing list of 2400 patients awaiting renal transplantation owing to a dearth of cadaver kidneys. The overall success rate at two years of renal transplantation is about 70% and rising. Following the high initial cost of a transplant, maintenance costs are acceptably low and 90% of patients who have been successfully transplanted can work normally.
Availability of artificial forms of renal replacement therapy depend roughly on a country's gross national product (GNP), and the UK is approximately 50% short of the required facilities. Though up to 85% of patients on dialysis are capable of work, their quality of life is suboptimal, with heavy psychological burdens on the patient and family.
Continuous ambulatory peritoneal dialysis costs £6700 per annum excluding any social benefits payable (Beardswortb & Goldsmith 1982) . The technique is quickly learnt but, owing to the risk of peritonitis, only a third of the patients can remain on this form of treatment for more than two years. The revenue cost of home artificial kidney treatment is similar and both these treatment methods undercut the cost of hospital dialysis by about 50%.
The high cost of treating renal failure should be seen in perspective against other chronic disabilities and is of a similar order:
Journal of the Royal Society of Medicine Volume 76 October 1983 887
Mr C W Venables (Newcastle) reported a costbenefit study of cimetidine versus surgery for peptic ulcer, a condition with a small mortality but a large morbidity. For a vagotomy operation the marginal cost (i.e. the cost of producing one more item of any sort) was calculated to be £653, Professor E Paykel (London) described a study of the economics of treating chronic neurotic outpatients (Paykel & Griffith 1983 , Mangen et al. 1983 ). For 10 years community psychiatric nurses (CPN) had been supervising patients, especially schizophrenics, in the local community. As a large number of chronic neurotic patients were regularly attending hospital outpatient (OP) clinics, it was decided to compare CPN and OP supervision using both clinical and economic criteria. Seventy-one patients were therefore randomized into 2 groups and assessed 6-monthly for 18 months.
There was no difference on symptom levels, social performance or family burden, but patient satisfaction was much higher in the CPN group. The overall mean cost per patient of psychiatric care was slightly but significantly higher in the OP group (£165 against £148) due to a little more inpatient treatment being given. However, when the total costs of care were considered (including general practice and other NHS resources plus social services), there was no significant difference. The major finding was that the small difference between the groups in the cost of the two regimens was completely swamped by these additional costs, even before and still more after social security payments were included (final total cost per patient £1361 for OP against £1504 for CPN). It would be misleading or futile to consider only the direct costs of treatment without regard to the wider implications. (Several speakers reiterated this point in other contexts.) Professor Paykel also gave some interesting comparative (1977) of which £555 was the ward (hotel) cost. There were additional costs such as an 8% recurrence rate, and 1% 'gastric cripples' requiring further treatment and social costs due to loss of work or possibly unemployment. There was also .an operative mortality rate of 0.5% and, depending on what value was put upon that, the total cost per surgical patient could vary widely.
In round figures, cimetidine healed 75% of duodenal ulcers in 4 weeks and a further 10% in 8 weeks. Seventy-seven of these 85 would require maintenance treatment, and sooner or later 27% of the original patients would require operation. Two other studies had shown that the number of operations had been reduced by 39.2 and 45%. In the Northern region the number of elective operations for duodenal ulcers was already falling before cimetidine was introduced in 1976. It then fell rapidly by 60% and reached a plateau. Emergency operations, except for perforation, have also fallen by 31%.
Simply by comparing the annual cost of treating 100 patients surgically or 100 patients with cimetidine, it was calculated that £38700 would be saved by using cimetidine.
Professor A Lant (London), speaking from the viewpoint of a physician and clinical pharmacologist, said that doctors have no choice but to establish a dialogue with economists because we cannot afford all that we have the technical capacity to do. He gave some examples of benefit derived from modern drugs but said that, on the other hand, misuse of drugs is common. For example, in one study over 50% of antibiotics were either not indicated or inappropriate. Therefore it is sensible that in many hospitals there is some voluntary restriction in the form of an antibiotic policy or local formulary. There is great scope for improving drug usage but comparatively little for financial saving when salaries account for over 70% of hospital expenditure and drugs only about 2%. It is important that any savings made should be reemployed locally or there is no incentive to save.
It is difficult to maintain a balanced view about the risks of drugs, which the media frequently exaggerate. As a result they stimulate public pressure for more and more testing. The development period for new drugs is now about 12 years and still increasing. There is of course a high, though rather inapparent, price for this. In fact no treatment is without risk. Side effects have quite often led to useful advances, especially in the case of diuretics, phenothiazines, MAO inhibitors and oral antidiabetics.
The cost-benefit of long-term treatment is sometimes finely balanced. For example, in recent years the value of oral antidiabetic drugs has been seriously questioned (Lancet 1975) , especially by clinicians in the United States and, whereas only a very small percentage of patients with mild hypertension will derive measurable benefit from treatment in terms of mortality or morbidity, all are exposed to the risks of medication and the cost of treating them could be very expensive.
In discussion, Professor HEM Kay (London) said that they had costed various cytotoxic drug regimens and had calculated that marrow transplants cost £10 000 per young life saved. When they were forced to economize, they decided they could save £155000 per year by closing the early diagnostic unit for lumps in the breast at the Royal Marsden Hospital. However, as a result of public pressure stimulated by television, the DHSS had instructed them to keep the unit open, although they knew that the resources could be better used elsewhere. It was another example of politics overriding rational decisions.
Dr D M Burley (London) said that although rifampicin is an expensive drug, its use has proved to be highly economic because it has halved the period of treatment necessary for tuberculosis and greatly reduced non-medication costs, especially hospital care. Dr M Chaput de Saintonge (London) reported that the DHSS had refused to support a trial which could have saved them £2 million per year on antibiotics. He also pointed to the difficulty of defining, let alone measuring, clinical benefit.
In conclusion, there was a general consensus that there is a need for more collaboration and that further meetings should be held with economists. Dr Mooney suggested two priority areas where they could help: with formularies and with drug trials. Drug evaluation has hitherto largely ignored economic considerations. Economists, like statisticians, should be consulted at an early stage.
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